DE60231394D1 - TRIAZOLOÄ4,5-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN PURINERGER REZEPTOREN - Google Patents
TRIAZOLOÄ4,5-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN PURINERGER REZEPTORENInfo
- Publication number
- DE60231394D1 DE60231394D1 DE60231394T DE60231394T DE60231394D1 DE 60231394 D1 DE60231394 D1 DE 60231394D1 DE 60231394 T DE60231394 T DE 60231394T DE 60231394 T DE60231394 T DE 60231394T DE 60231394 D1 DE60231394 D1 DE 60231394D1
- Authority
- DE
- Germany
- Prior art keywords
- receptors
- alkyl
- aryl
- disorder
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000005557 antagonist Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 208000002193 Pain Diseases 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 108050000203 Adenosine receptors Proteins 0.000 abstract 1
- 102000009346 Adenosine receptors Human genes 0.000 abstract 1
- 101150051188 Adora2a gene Proteins 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 108010080192 Purinergic Receptors Proteins 0.000 abstract 1
- 102000000033 Purinergic Receptors Human genes 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 150000001721 carbon Chemical class 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0100624.6A GB0100624D0 (en) | 2001-01-10 | 2001-01-10 | Chemical compounds VII |
| PCT/GB2002/000091 WO2002055083A1 (en) | 2001-01-10 | 2002-01-10 | TRIAZOLO[4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60231394D1 true DE60231394D1 (de) | 2009-04-16 |
Family
ID=9906571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60231394T Expired - Lifetime DE60231394D1 (de) | 2001-01-10 | 2002-01-10 | TRIAZOLOÄ4,5-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN PURINERGER REZEPTOREN |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US7141575B2 (de) |
| EP (1) | EP1392312B1 (de) |
| JP (2) | JP4287146B2 (de) |
| KR (1) | KR100913845B1 (de) |
| CN (3) | CN101214248A (de) |
| AT (1) | ATE424207T1 (de) |
| AU (1) | AU2002219355B2 (de) |
| BR (1) | BR0206559A (de) |
| CA (1) | CA2433453C (de) |
| CZ (1) | CZ301916B6 (de) |
| DE (1) | DE60231394D1 (de) |
| DK (1) | DK1392312T3 (de) |
| ES (1) | ES2323301T3 (de) |
| GB (1) | GB0100624D0 (de) |
| HK (1) | HK1061206A1 (de) |
| HR (1) | HRP20030533A2 (de) |
| HU (1) | HUP0401047A3 (de) |
| IL (2) | IL156713A0 (de) |
| MX (1) | MXPA03006165A (de) |
| NO (1) | NO328475B1 (de) |
| NZ (1) | NZ527248A (de) |
| PL (1) | PL363101A1 (de) |
| PT (1) | PT1392312E (de) |
| RS (1) | RS51121B (de) |
| RU (1) | RU2317084C2 (de) |
| WO (1) | WO2002055083A1 (de) |
| ZA (1) | ZA200305087B (de) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2842424A1 (fr) * | 2002-07-22 | 2004-01-23 | Univ Paris 7 Denis Diderot | Utilisation du nad ou de l'un de ses analogues, substrat des mono-adp-ribosyl tranferases, pour la preparation d'un medicament destine au traitement des pathologies liees aux recepteurs purinergiques |
| DE60335294D1 (de) * | 2002-12-19 | 2011-01-20 | Schering Corp | Dlung des extrapyramidalen syndroms |
| TWI355381B (en) | 2003-04-23 | 2012-01-01 | Schering Corp | 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-tri |
| WO2005028434A2 (en) * | 2003-09-18 | 2005-03-31 | Conforma Therapeutics Corporation | Novel heterocyclic compounds as hsp90-inhibitors |
| AU2005236059B2 (en) | 2004-04-21 | 2009-01-15 | Schering Corporation | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists |
| US7910613B2 (en) | 2004-09-22 | 2011-03-22 | H. Lundbeck A/S | 2-acylaminothiazole derivatives |
| CN100398542C (zh) * | 2005-03-18 | 2008-07-02 | 北京大学 | 具有抗hiv活性的取代1,2,3-三唑并嘧啶新化合物，制备方法及用途 |
| CA2602257A1 (en) * | 2005-03-30 | 2006-10-05 | Conforma Therapeutics Corporation | Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors |
| US7674912B2 (en) | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
| US7851478B2 (en) | 2005-06-07 | 2010-12-14 | Kyowa Hakko Kirin Co., Ltd. | Agent for preventing and/or treating movement disorder |
| CA2617817C (en) * | 2005-08-02 | 2014-05-27 | Kyowa Hakko Kogyo Co., Ltd. | Thiazole derivatives for treating or preventing sleep disorders |
| ATE538123T1 (de) | 2005-09-19 | 2012-01-15 | Schering Corp | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors |
| PE20070521A1 (es) | 2005-09-23 | 2007-07-13 | Schering Corp | 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a |
| US20070105874A1 (en) * | 2005-09-23 | 2007-05-10 | Conforma Therapeutics Corporation | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
| DE102005049954A1 (de) * | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
| US20080027079A1 (en) * | 2006-06-22 | 2008-01-31 | Board Of Regents, University Of Texas System | Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity |
| WO2008086201A1 (en) * | 2007-01-05 | 2008-07-17 | Biogen Idec Ma Inc. | Polymorphs and solvates of a pharmaceutical and methods of making |
| EP2117313A4 (de) * | 2007-01-12 | 2011-04-27 | Biogen Idec Inc | Pharmazutika, zusammensetzungen und verfahren zu ihrer herstellung und verwendung |
| FR2915198B1 (fr) * | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| FR2915197B1 (fr) * | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
| FR2915199B1 (fr) * | 2007-04-18 | 2010-01-22 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique. |
| US8415353B2 (en) | 2008-03-04 | 2013-04-09 | Merck Sharp & Dohme Corp. | Amino-quinoxaline and amino-quinoline compounds for use as adenosine A2a receptor antagonists |
| EP2262811B1 (de) | 2008-03-04 | 2016-04-27 | Merck Sharp & Dohme Corp. | 1,2,4-triazolo[4,3-c]pyrimidin-3-on- und pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-3-onverbindungen zur verwendung als antagonisten des adenosin-a2a-rezeptors |
| TWI473614B (zh) | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
| WO2009152521A2 (en) * | 2008-06-13 | 2009-12-17 | Parkinson's Institute | Diagnosis of neurodegenerative disorders |
| GB0906579D0 (en) | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| EP2322223A4 (de) * | 2008-07-23 | 2012-08-22 | Kyowa Hakko Kirin Co Ltd | Therapeutisches mittel gegen migräne |
| AU2009330821B2 (en) * | 2008-12-24 | 2015-06-11 | Bial - Portela & Ca, S.A. | Pharmaceutical compounds |
| JP5765239B2 (ja) | 2009-03-13 | 2015-08-19 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物 |
| WO2011050160A1 (en) * | 2009-10-22 | 2011-04-28 | Biogen Idec Ma Inc. | Pharmaceuticals, compositions and methods of making and using the same |
| WO2011055391A1 (en) | 2009-11-09 | 2011-05-12 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| US8435994B2 (en) | 2009-11-16 | 2013-05-07 | Merck Sharp & Dohme Corp. | Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists |
| CN102822150B (zh) | 2010-02-05 | 2014-12-03 | 赫普泰雅治疗有限公司 | 1,2,4-三嗪-4-胺衍生物 |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| WO2016126570A1 (en) | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
| US10912776B2 (en) | 2015-12-24 | 2021-02-09 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
| CN107021963A (zh) * | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| EP3548083A1 (de) | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Verfahren zur modulation von car-t-zellen |
| MA46963A (fr) | 2016-12-03 | 2019-10-09 | Juno Therapeutics Inc | Méthodes pour déterminer le dosage de céllules car-t |
| CN106883191A (zh) * | 2017-01-19 | 2017-06-23 | 华侨大学 | 一种n‑取代苯并三氮唑衍生物的制备方法 |
| US11066413B2 (en) * | 2017-03-07 | 2021-07-20 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof |
| US10654825B2 (en) | 2017-03-30 | 2020-05-19 | Corvus Pharmaceuticals, Inc. | Processes for making triazolo[4,5D] pyramidine derivatives and intermediates thereof |
| EP3606531A4 (de) | 2017-04-04 | 2021-04-28 | Corvus Pharmaceuticals, Inc. | Verfahren zur behandlung von krebs |
| MX2019012017A (es) | 2017-04-07 | 2020-02-12 | Juno Therapeutics Inc | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. |
| CN111225675B (zh) | 2017-06-02 | 2024-05-03 | 朱诺治疗学股份有限公司 | 使用过继细胞疗法治疗的制品和方法 |
| US20220225597A1 (en) | 2017-06-29 | 2022-07-21 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| AU2018360800A1 (en) | 2017-11-01 | 2020-05-14 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen (BCMA) |
| BR112020008323A2 (pt) | 2017-11-01 | 2020-11-03 | Juno Therapeutics Inc | anticorpos e receptores de antígenos quiméricos específicos para antígeno de maturação de células b |
| EP3716980A1 (de) | 2017-12-01 | 2020-10-07 | Juno Therapeutics, Inc. | Verfahren zur dosieren und modulierung von genetisch veränderten zellen |
| WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| US20200316077A1 (en) | 2017-12-19 | 2020-10-08 | Impetis Biosciences Ltd. | Pharmaceutical composition for the treatment of cancer |
| KR20200106176A (ko) | 2018-01-04 | 2020-09-11 | 임페티스 바이오사이언시즈 엘티디. | 삼환식 화합물, 삼환식 화합물을 포함하는 조성물 및 이의 의약적 용도 |
| EP3814357B1 (de) * | 2018-06-27 | 2024-05-01 | PTC Therapeutics, Inc. | Heterocyclische und heteroaryl verbindungen zur behandlung von morbus huntington |
| WO2020068583A1 (en) * | 2018-09-27 | 2020-04-02 | Corvus Pharmaceuticals, Inc. | Processes for making triazolo [4,5d] pyramidine derivatives and intermediates thereof |
| CA3117419A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| AU2019374103A1 (en) | 2018-11-01 | 2021-05-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) |
| BR112021009420A2 (pt) | 2018-11-16 | 2021-11-23 | Juno Therapeutics Inc | Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b |
| KR20210117260A (ko) | 2018-11-30 | 2021-09-28 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료방법 |
| US20220096651A1 (en) | 2019-01-29 | 2022-03-31 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| CN110251518A (zh) * | 2019-06-28 | 2019-09-20 | 青岛科技大学 | 1,2,4-三氮唑类杂环化合物在制备预防或治疗与中枢系统相关疾病药物中的应用 |
| CN111825698B (zh) | 2019-07-30 | 2021-10-15 | 杭州阿诺生物医药科技有限公司 | 腺苷受体拮抗剂 |
| CN112592346B (zh) | 2019-07-30 | 2022-04-26 | 厦门宝太生物科技股份有限公司 | 一种a2a和/或a2b抑制剂中间体的制备方法 |
| WO2021050688A1 (en) * | 2019-09-10 | 2021-03-18 | X-Chem, Inc. | Compounds and uses thereof |
| WO2021080980A1 (en) * | 2019-10-22 | 2021-04-29 | Alphala Co., Ltd. | Pyrimidine amide compounds and use thereof |
| CN115916223A (zh) | 2020-04-10 | 2023-04-04 | 朱诺治疗学股份有限公司 | 与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途 |
| CN111333655B (zh) * | 2020-04-13 | 2021-07-13 | 武汉工程大学 | 一种三唑并嘧啶类化合物及其制备方法和应用 |
| WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| WO2024129778A2 (en) | 2022-12-13 | 2024-06-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56131587A (en) | 1980-03-18 | 1981-10-15 | Ss Pharmaceut Co Ltd | 7-substituted triazolopyrimidine derivative and its preparation |
| JPS56131586A (en) | 1980-03-18 | 1981-10-15 | Ss Pharmaceut Co Ltd | Triazolopyrimidine derivative and its preparation |
| JPS5962595A (ja) | 1982-09-30 | 1984-04-10 | Ss Pharmaceut Co Ltd | ３，５，７―トリ置換―トリアゾロピリミジン誘導体 |
| DE3304330A1 (de) | 1983-02-09 | 1984-08-09 | Basf Ag, 6700 Ludwigshafen | Neue 2h-v-triazolyl(4,5-d)-pyrimidine und deren verwendung |
| JPS60140335A (ja) | 1983-12-28 | 1985-07-25 | Konishiroku Photo Ind Co Ltd | 熱現像カラ−感光材料 |
| US5204353A (en) | 1987-04-07 | 1993-04-20 | Ciba-Geigy Corporation | 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith |
| US5194581A (en) | 1989-03-09 | 1993-03-16 | Leong Kam W | Biodegradable poly(phosphoesters) |
| CZ101496A3 (en) | 1993-10-12 | 1996-11-13 | Du Pont Merck Pharma | N-alkyl-n-aryl-pyrimidinamines and derivatives thereof |
| CZ297200B6 (cs) | 1995-07-11 | 2006-09-13 | Astrazeneca Ab | Nové inhibitory agregace krevních desticek |
| ZA971896B (en) * | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| HUP9903965A3 (en) * | 1996-08-28 | 2002-02-28 | Pfizer | Substituted 6,5-hetero-bicyclic derivatives |
| DE69820866T2 (de) * | 1997-03-24 | 2004-12-30 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-DERIVATE |
| US5912225A (en) * | 1997-04-14 | 1999-06-15 | Johns Hopkins Univ. School Of Medicine | Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same |
| KR20010020432A (ko) * | 1997-04-30 | 2001-03-15 | 토마스 씨. 서 | 폴리(고리지방족 포스포에스테르) 화합물로 이루어진 생분해성 조성물, 약품 및 그의 이용방법 |
| US6028163A (en) | 1997-06-27 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Solution polymerization of high molecular weight poly(phosphoesters) in toluene |
| US6103737A (en) * | 1997-07-03 | 2000-08-15 | Dupont Pharmaceuticals Company | Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists |
| US5939432A (en) * | 1997-10-29 | 1999-08-17 | Medco Research, Inc. | Thiophenes useful for modulating the adenosine receptor |
| WO1999026627A1 (en) | 1997-11-26 | 1999-06-03 | Cerebrus Limited | (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders |
| CA2315736A1 (en) | 1998-01-05 | 1999-07-15 | Eisai Co., Ltd. | Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus |
| GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
| GB9915437D0 (en) | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| AU778450B2 (en) | 1999-07-02 | 2004-12-09 | Eisai R&D Management Co., Ltd. | Fused imidazole compounds and remedies for diabetes mellitus |
-
2001
- 2001-01-10 GB GBGB0100624.6A patent/GB0100624D0/en not_active Ceased
-
2002
- 2002-01-10 EP EP02729452A patent/EP1392312B1/de not_active Expired - Lifetime
- 2002-01-10 NZ NZ527248A patent/NZ527248A/en active IP Right Revival
- 2002-01-10 BR BR0206559-2A patent/BR0206559A/pt not_active Application Discontinuation
- 2002-01-10 WO PCT/GB2002/000091 patent/WO2002055083A1/en active IP Right Grant
- 2002-01-10 CN CNA2008100024015A patent/CN101214248A/zh active Pending
- 2002-01-10 AT AT02729452T patent/ATE424207T1/de active
- 2002-01-10 PT PT02729452T patent/PT1392312E/pt unknown
- 2002-01-10 CA CA2433453A patent/CA2433453C/en not_active Expired - Lifetime
- 2002-01-10 PL PL02363101A patent/PL363101A1/xx not_active Application Discontinuation
- 2002-01-10 US US10/250,942 patent/US7141575B2/en not_active Expired - Lifetime
- 2002-01-10 IL IL15671302A patent/IL156713A0/xx unknown
- 2002-01-10 CN CNA028063031A patent/CN1496262A/zh active Pending
- 2002-01-10 CZ CZ20031955A patent/CZ301916B6/cs not_active IP Right Cessation
- 2002-01-10 ES ES02729452T patent/ES2323301T3/es not_active Expired - Lifetime
- 2002-01-10 DE DE60231394T patent/DE60231394D1/de not_active Expired - Lifetime
- 2002-01-10 DK DK02729452T patent/DK1392312T3/da active
- 2002-01-10 RS YUP-555/03A patent/RS51121B/sr unknown
- 2002-01-10 RU RU2003124651/04A patent/RU2317084C2/ru not_active IP Right Cessation
- 2002-01-10 AU AU2002219355A patent/AU2002219355B2/en not_active Ceased
- 2002-01-10 ZA ZA200305087A patent/ZA200305087B/xx unknown
- 2002-01-10 HU HU0401047A patent/HUP0401047A3/hu unknown
- 2002-01-10 CN CN200910164664A patent/CN101691370A/zh active Pending
- 2002-01-10 JP JP2002555817A patent/JP4287146B2/ja not_active Expired - Lifetime
- 2002-01-10 KR KR1020037009240A patent/KR100913845B1/ko not_active IP Right Cessation
- 2002-01-10 MX MXPA03006165A patent/MXPA03006165A/es active IP Right Grant
-
2003
- 2003-06-30 HR HR20030533A patent/HRP20030533A2/hr not_active Application Discontinuation
- 2003-06-30 IL IL156713A patent/IL156713A/en not_active IP Right Cessation
- 2003-07-09 NO NO20033146A patent/NO328475B1/no not_active IP Right Cessation
-
2004
- 2004-06-15 HK HK04104319.2A patent/HK1061206A1/xx not_active IP Right Cessation
-
2006
- 2006-08-22 US US11/507,625 patent/US7405219B2/en not_active Expired - Lifetime
-
2007
- 2007-12-20 US US12/003,110 patent/US7589097B2/en not_active Expired - Lifetime
-
2008
- 2008-12-02 JP JP2008308004A patent/JP5202259B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60231394D1 (de) | TRIAZOLOÄ4,5-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN PURINERGER REZEPTOREN | |
| DE60228414D1 (de) | Pyrrolo 2,3-d pyrimidine und deren verwendung als purinreceptor antagonisten | |
| YU55603A (sh) | Derivati purina kao antagonisti purinergiskog receptora | |
| DE60228817D1 (de) | THIENO(3,2-d)PYRIMIDINE UND FURANO(3,2-d)PYRIMIDINE UND DEREN VERWENDUNG ALS ANTAGONISTEN AN PURINERGEN REZEPTOREN | |
| PE20091268A1 (es) | Derivados heterociclicos como inhibidores de pi3 quinasa | |
| PE20010430A1 (es) | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
| HUP0102300A2 (hu) | Diazepinszármazékok alkalmazása szomatosztatin-receptor által befolyásolt betegségek kezelésére szánt gyógyszerek előállítására, valamint új vegyületek | |
| ATE325796T1 (de) | Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente | |
| ATE307132T1 (de) | Purin derivate als a2b adenosin rezeptor antagonisten | |
| EE200200148A (et) | Kinasoliini derivaadid, nende valmistamise meetodning kasutamine | |
| PE20061078A1 (es) | Derivados de piridotienopirimidina como inhibidores de la fosfodiesterasa 4 (pde4) | |
| KR930002349A (ko) | 트리아졸로피리미딘 유도체, 그의 제조방법 및 그를 포함하는 조성물 | |
| NO20022976D0 (no) | 2-(1H-indol-3yl)-2-okso-acetamider med antitumoraktivitet | |
| DE69919478D1 (de) | 7-Aminopyrido(2,3-d)-pyrimidine Derivate zur Behandlung von Bronchialasthma | |
| ES2193047T3 (es) | (3,4 dihydro-2h-benzo(1,4) oxazinilmetil)(3-(1h-indol-3-il)-alquil)-aminas. | |
| ATE238334T1 (de) | Nucleosid-derivate mit photolabilen schutzgruppen | |
| ES2182775T3 (es) | Derivados de ciclohexano 1,4-disustituidos para el tratamiento de la depresion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |